TY - JOUR
T1 - Interferon-α-2b as an adjuvant therapy prolongs survival of patients with previously resected oral muscosal melanoma
AU - Wang, R.
AU - Jing, G.
AU - Lv, J.
AU - Song, H.
AU - Li, C.
AU - Wang, X.
AU - Xia, W.
AU - Wu, Y.
AU - Ren, G.
AU - Guo, W.
N1 - Publisher Copyright:
© FUNPEC-RP.
PY - 2015/10/5
Y1 - 2015/10/5
N2 - Two major subtypes of melanoma include cutaneous melanoma and mucosal melanoma. The latter type is rare and usually occurs in the head and neck region. High-dose interferon-α-2b (IFN-α-2b) has proven effective in the treatment of cutaneous melanoma. Recently, a regimen of temozolomide plus cisplatin was reported more likely to improve relapse-free survival and overall survival than high-dose IFN-α-2b for mucosal melanoma. We conducted this study to analyze the therapeutic effect of high-dose IFN-α-2b for patients with oral mucosal melanoma who had received prior chemotherapy. One hundred and seventeen patients with stage III-IVa oral mucosal melanoma who had received chemotherapy were analyzed. The overall survival and relapse-free survival were compared between the patients with/without high-dose IFN-α-2b. The results indicate that the IFN-α-2b treatment group had a longer relapse-free survival rate (P = 0.0169) as compared to the control group. However, the overall survival was not significant between the two groups (P = 0.096), except in patients in stage IVa, whose overall survival increased by 20 months (P = 0.0146). The adverse reactions included a drug-induced influenza-like syndrome, gastrointestinal responses, myelosuppression, and hepatoxicity, which were predominantly of grade 1-2 and reversible. Thus, patients with resected oral mucosal melanoma, even those who have received chemotherapy, could benefit from the treatment of high-dose IFN-α-2b.
AB - Two major subtypes of melanoma include cutaneous melanoma and mucosal melanoma. The latter type is rare and usually occurs in the head and neck region. High-dose interferon-α-2b (IFN-α-2b) has proven effective in the treatment of cutaneous melanoma. Recently, a regimen of temozolomide plus cisplatin was reported more likely to improve relapse-free survival and overall survival than high-dose IFN-α-2b for mucosal melanoma. We conducted this study to analyze the therapeutic effect of high-dose IFN-α-2b for patients with oral mucosal melanoma who had received prior chemotherapy. One hundred and seventeen patients with stage III-IVa oral mucosal melanoma who had received chemotherapy were analyzed. The overall survival and relapse-free survival were compared between the patients with/without high-dose IFN-α-2b. The results indicate that the IFN-α-2b treatment group had a longer relapse-free survival rate (P = 0.0169) as compared to the control group. However, the overall survival was not significant between the two groups (P = 0.096), except in patients in stage IVa, whose overall survival increased by 20 months (P = 0.0146). The adverse reactions included a drug-induced influenza-like syndrome, gastrointestinal responses, myelosuppression, and hepatoxicity, which were predominantly of grade 1-2 and reversible. Thus, patients with resected oral mucosal melanoma, even those who have received chemotherapy, could benefit from the treatment of high-dose IFN-α-2b.
KW - Adjuvant treatment
KW - Chemotherapy
KW - Interferon-α-2b
KW - Oral mucosal melanoma
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=84943631204&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84943631204&partnerID=8YFLogxK
U2 - 10.4238/2015.October.5.8
DO - 10.4238/2015.October.5.8
M3 - Article
C2 - 26505342
AN - SCOPUS:84943631204
SN - 1676-5680
VL - 14
SP - 11944
EP - 11954
JO - Genetics and Molecular Research
JF - Genetics and Molecular Research
IS - 4
ER -